相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Renal Proximal Tubule Cell Cannabinoid-1 Receptor Regulates Bone Remodeling and Mass via a Kidney-to-Bone Axis
Saja Baraghithy et al.
CELLS (2021)
Five-in-One: Simultaneous isolation of multiple major liver cell types from livers of normal and NASH mice
Ye Zhou et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2021)
Cannabinoid receptor 1 signaling in hepatocytes and stellate cells does not contribute to NAFLD
Simeng Wang et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
The therapeutic potential of second and third generation CB1R antagonists
Resat Cinar et al.
PHARMACOLOGY & THERAPEUTICS (2020)
Reversal of diet-induced hepatic steatosis by peripheral CB1 receptor blockade in mice is p53/miRNA-22/SIRT1/PPARα dependent
Shahar Azar et al.
MOLECULAR METABOLISM (2020)
Protocol Protocol for Primary Mouse Hepatocyte Isolation
Meital Charni-Natan et al.
STAR PROTOCOLS (2020)
Cannabinoid-1 receptor regulates mitochondrial dynamics and function in renal proximal tubular cells
Adi Drori et al.
DIABETES OBESITY & METABOLISM (2019)
Circulating Endocannabinoids Are Reduced Following Bariatric Surgery and Associated with Improved Metabolic Homeostasis in Humans
Shahar Azar et al.
OBESITY SURGERY (2019)
Muscle cannabinoid 1 receptor regulates Il-6 and myostatin expression, governing physical performance and whole-body metabolism
Isabel Gonzalez-Mariscal et al.
FASEB JOURNAL (2019)
Endocannabinoid System in Hepatic Glucose Metabolism, Fatty Liver Disease, and Cirrhosis
Ivonne Bazwinsky-Wutschke et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Cannabis: From a Plant That Modulates Feeding Behaviors toward Developing Selective Inhibitors of the Peripheral Endocannabinoid System for the Treatment of Obesity and Metabolic Syndrome
Shira Hirsch et al.
TOXINS (2019)
Overcoming the Psychiatric Side Effects of the Cannabinoid CB1 Receptor Antagonists: Current Approaches for Therapeutics Development
Thuy Nguyen et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2019)
Analysis of Direct Effects of the CB1 Receptor Antagonist Rimonabant on Fatty Acid Oxidation and Glycogenolysis in Liver and Muscle Cells in vitro
G. A. Mueller et al.
BIOCHEMISTRY-MOSCOW (2019)
Cannabinoid-1 Receptor Antagonism Improves Glycemic Control and Increases Energy Expenditure Through Sirtuin-1/Mechanistic Target of Rapamycin Complex 2 and 5′Adenosine Monophosphate-Activated Protein Kinase Signaling
Jie Liu et al.
HEPATOLOGY (2019)
Modulation of Renal GLUT2 by the Cannabinoid-1 Receptor: Implications for the Treatment of Diabetic Nephropathy
Liad Hinden et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
Absence of cannabinoid 1 receptor in beta cells protects against high-fat/high-sugar diet-induced beta cell dysfunction and inflammation in murine islets
Isabel Gonzalez-Mariscal et al.
DIABETOLOGIA (2018)
The therapeutic potential of targeting the peripheral endocannabinoid/CB1 receptor system
Joseph Tam et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2018)
Serum Levels of Endocannabinoids are Independently Associated with Nonalcoholic Fatty Liver Disease
Shira Zelber-Sagi et al.
OBESITY (2017)
Adipocyte cannabinoid receptor CB1 regulates energy homeostasis and alternatively activated macrophages
Inigo Ruiz de Azua et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Proximal Tubular Cannabinoid-1 Receptor Regulates Obesity-Induced CKD
Shiran Udi et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Decreasing CB1 receptor signaling in Kupffer cells improves insulin sensitivity in obese mice
Tony Jourdan et al.
MOLECULAR METABOLISM (2017)
Protective effect of rimonabant, a canabinoid receptor 1 antagonist, on nonalcoholic fatty liver disease in a rat model through modulation of the hepatic expression of activin A and follistatin
Noha I. Hussien et al.
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY (2017)
The effect of cannabinoid receptor 1 blockade on hepatic free fatty acid profile in mice with nonalcoholic fatty liver disease
Bojan Jorgacevic et al.
CHEMISTRY AND PHYSICS OF LIPIDS (2017)
Endocannabinoids signaling: Molecular mechanisms of liver regulation and diseases
Mi Wang et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2016)
Nanoparticle-liver interactions: Cellular uptake and hepatobiliary elimination
Yi-Nan Zhang et al.
JOURNAL OF CONTROLLED RELEASE (2016)
Targeting the endocannabinoid/CB1 receptor system for treating obesity in Pradere-Willi syndrome
Ibrahim Knani et al.
MOLECULAR METABOLISM (2016)
Cannabinoid antagonist in nanostructured lipid carriers (NLCs): design, characterization and in vivo study
Elisabetta Esposito et al.
MATERIALS SCIENCE & ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS (2015)
Mesoscale Nanoparticles Selectively Target the Renal Proximal Tubule Epithelium
Ryan M. Williams et al.
NANO LETTERS (2015)
Rimonabant Improves Oxidative/Nitrosative Stress in Mice with Nonalcoholic Fatty Liver Disease
Bojan JorgaIevic et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2015)
Effects of rimonabant on the development of single dose-induced behavioral sensitization to ethanol, morphine and cocaine in mice
Eduardo A. V. Marinho et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2015)
Role of adiponectin in the metabolic effects of cannabinoid type 1 receptor blockade in mice with diet-induced obesity
Joseph Tam et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2014)
Hepatic Cannabinoid-1 Receptors Mediate Diet-Induced Insulin Resistance by Increasing De Novo Synthesis of Long-Chain Ceramides
Resat Cinar et al.
HEPATOLOGY (2014)
Inhibiting CB1 receptors improves lipogenesis in an in vitro non-alcoholic fatty liver disease model
Dongmei Shi et al.
LIPIDS IN HEALTH AND DISEASE (2014)
Circulating endocannabinoids in insulin sensitive vs. Insulin resistant obese postmenopausal women. A MONET group study
Joseph Abdulnour et al.
OBESITY (2014)
Cannabinoid signaling and liver therapeutics
Ariane Mallat et al.
JOURNAL OF HEPATOLOGY (2013)
Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity
F. J. Meye et al.
MOLECULAR PSYCHIATRY (2013)
Dissociable effects of CB1 receptor blockade on anxiety-like and consummatory behaviors in the novelty-induced hypophagia test in mice
Joyonna C. Gamble-George et al.
PSYCHOPHARMACOLOGY (2013)
Factors Controlling Nanoparticle Pharmacokinetics: An Integrated Analysis and Perspective
S. M. Moghimi et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 52 (2012)
Peripheral Cannabinoid-1 Receptor Inverse Agonism Reduces Obesity by Reversing Leptin Resistance
Joseph Tam et al.
CELL METABOLISM (2012)
Hepatic Cannabinoid Receptor-1 Mediates Diet-Induced Insulin Resistance via Inhibition of Insulin Signaling and Clearance in Mice
Jie Liu et al.
GASTROENTEROLOGY (2012)
Antagonism of peripheral hepatic cannabinoid receptor-1 improves liver lipid metabolism in mice: Evidence from cultured explants
Tony Jourdan et al.
HEPATOLOGY (2012)
Weight loss induced by rimonabant is associated with an altered leptin expression and hypothalamic leptin signaling in diet-induced obese mice
Paolo Lazzari et al.
BEHAVIOURAL BRAIN RESEARCH (2011)
Endocannabinoids in Liver Disease
Joseph Tam et al.
HEPATOLOGY (2011)
Rimonabant improves cholesterol, insulin resistance and markers of non-alcoholic fatty liver in morbidly obese patients: a retrospective cohort study
A. S. Wierzbicki et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2011)
Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment
Briohny W. Smith et al.
NATURE REVIEWS ENDOCRINOLOGY (2011)
The Central Cannabinoid CB1 Receptor Is Required for Diet-Induced Obesity and Rimonabant's Antiobesity Effects in Mice
Zhen Pang et al.
OBESITY (2011)
Rimonabant, a Cannabinoid Receptor Type 1 Inverse Agonist, Inhibits Hepatocyte Lipogenesis by Activating Liver Kinase B1 and AMP-Activated Protein Kinase Axis Downstream of Gαi/o Inhibition
Hong Min Wu et al.
MOLECULAR PHARMACOLOGY (2011)
CB1 Antagonism Exerts Specific Molecular Effects on Visceral and Subcutaneous Fat and Reverses Liver Steatosis in Diet-Induced Obese Mice
Tony Jourdan et al.
DIABETES (2010)
Effect of Rimonabant on Glycemic Control in Insulin-Treated Type 2 Diabetes: The ARPEGGIO Trial
Priscilla A. Hollander et al.
DIABETES CARE (2010)
Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity
Joseph Tam et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Cannabinoid CB1 receptor expression in relation to visceral adipose depots, endocannabinoid levels, microvascular damage, and the presence of the Cnr1 A3813G variant in humans
Marica Bordicchia et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2010)
Effects of the cannabinoid CB1 antagonist rimonabant on hepatic mitochondrial function in rats fed a high-fat diet
Melissa Flamment et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2009)
Effect of Rimonabant on the High-Triglyceride/Low-HDL-Cholesterol Dyslipidemia, Intraabdominal Adiposity, and Liver Fat The ADAGIO-Lipids Trial
Jean-Pierre Despres et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2009)
Cannabinoid type 1 receptors in human skeletal muscle cells participate in the negative crosstalk between fat and muscle
K. Eckardt et al.
DIABETOLOGIA (2009)
Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects
Vincenzo Di Marzo et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009)
Beneficial effect of a chronic treatment with rimonabant on pancreatic function and β-cell morphology in Zucker Fatty rats
Valerie F. Duvivier et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2009)
Food Intake-independent Effects of CB1 Antagonism on Glucose and Lipid Metabolism
Daniela Cota et al.
OBESITY (2009)
SERENADE: The Study Evaluating Rimonabant Efficacy in Drug-Naive Diabetic Patients Effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes
Julio Rosenstock et al.
DIABETES CARE (2008)
Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice
Douglas Osei-Hyiaman et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Non-alcoholic fatty liver disease: The mist gradually clears
Nimantha Mark Wilfred de Alwis et al.
JOURNAL OF HEPATOLOGY (2008)
The endocannabinoid system and the control of glucose homeostasis
R. Nogueiras et al.
JOURNAL OF NEUROENDOCRINOLOGY (2008)
Pharmacokinetics and biodistribution of nanoparticles
Shyh-Dar Li et al.
MOLECULAR PHARMACEUTICS (2008)
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Frank Alexis et al.
MOLECULAR PHARMACEUTICS (2008)
End of the line for cannabinoid receptor 1 as an anti-obesity target?
Dan Jones
NATURE REVIEWS DRUG DISCOVERY (2008)
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
Robin Christensen et al.
LANCET (2007)
The endocannabinoid 2-arachidonoyl glycerol induces death of hepatic stellate cells via mitochondrial reactive oxygen species
Soeren V. Siegmund et al.
FASEB JOURNAL (2007)
Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats
Magali Gary-Bobo et al.
HEPATOLOGY (2007)
Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men
M. Cote et al.
INTERNATIONAL JOURNAL OF OBESITY (2007)
Rimonabant in obese patients with type 2 diabetes
Michael D. Randall et al.
LANCET (2007)
Ontogeny of fear-, anxiety- and depression-related behavior across adolescence in C57BL/6J mice
Kathryn Hefner et al.
BEHAVIOURAL BRAIN RESEARCH (2007)
The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism - or inverse agonism - as potential obesity treatment and other therapeutic use
S. Xie et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2007)
Anandamide mediates hyperdynamic circulation in cirrhotic rats via CB1 and VR1 receptors
L. Moezi et al.
BRITISH JOURNAL OF PHARMACOLOGY (2006)
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study
Andre J. Scheen et al.
LANCET (2006)
Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity
Matthias Blueher et al.
DIABETES (2006)
Regulation, function, and dysregulation of endocannabinoids in models of adipose and β-pancreatic cells and in obesity and hyperglycemia
Isabel Matias et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis
Fatima Teixeira-Clerc et al.
NATURE MEDICINE (2006)
Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients - RIO-North America: A randomized controlled trial
F Pi-Sunyer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles
DE Owens et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2006)
The endocannabinoid system as an emerging target of pharmacotherapy
Pal Pacher et al.
PHARMACOLOGICAL REVIEWS (2006)
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
JP Despres et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activation of the peripheral endocannabinoid system in human obesity
S Engeli et al.
DIABETES (2005)
The role of CB1 receptors in sweet versus fat reinforcement:: effect of CB1 receptor deletion, CB1 receptor antagonism (SR141716A) and CB1 receptor agonism (CP-55940)
SJ Ward et al.
BEHAVIOURAL PHARMACOLOGY (2005)
The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance
O Jbilo et al.
FASEB JOURNAL (2005)
CB1 cannabinoid receptor-mediated modulation of food intake in mice
JL Wiley et al.
BRITISH JOURNAL OF PHARMACOLOGY (2005)
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients:: 1-year experience from the RIO-Europe study
LF Van Gaal et al.
LANCET (2005)
Increased anandamide induced relaxation in mesenteric arteries of cirrhotic rats:: role of cannabinoid and vanilloid receptors
M Domenicali et al.
GUT (2005)
Vasodilator mRNA levels are increased in the livers of portal hypertensive NO-synthase 3-deficient mice
E Biecker et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2004)
Non-alcoholic steatohepatitis in type 2 diabetes mellitus
P Gupte et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2004)
Endocannabinoids acting at vascular CB, receptors mediate the vasodilated state in advanced liver cirrhosis
S Bátkai et al.
NATURE MEDICINE (2001)
Leptin-regulated endocannabinoids are involved in maintaining food intake
V Di Marzo et al.
NATURE (2001)
Inhibitory effects of SR141716A on G-protein activation in rat brain
LJ Sim-Selley et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2001)
Effects of SR141716A, a central cannabinoid receptor antagonist, on food-maintained responding
CS Freedland et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2000)
分享论文
